CPT code 87798 – Infectious agent detection, not otherwise specified

Key takeaways

CPT Code 87798 detects infectious agents by nucleic acid amplification when no specific code exists for that organism

The specific-code-always-wins rule: if a dedicated 87XXX code exists for the target organism, 87798 cannot be used

Bill one unit per analyte tested; Modifier 59 applies when multiple NOS organisms are tested in the same encounter

Pabau’s claims management software supports clean claim submission and tracks denial patterns for molecular lab codes

CPT Code 87798: Official descriptor and code details

The American Medical Association describes CPT Code 87798 as follows. Infectious agent detection by nucleic acid (DNA or RNA); not otherwise specified, amplified probe technique, each organism. The code sits in the 87XXX microbiology family and is reported under the Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule.

What CPT 87798 covers and what it excludes

CPT 87798 applies when a laboratory runs nucleic acid amplification testing on a direct specimen for an infectious agent with no dedicated CPT code. The organism has to lack a specific code in the 87XXX range.

Where a specific code exists, that code must be used instead. Payer LCD policies treat 87798 reported in place of a specific code as a billing error. Map every organism on your test menu to its code inside the order entry system, so the substitution is caught before the test goes out.

Organisms typically billed under 87798

These are organisms for which no specific NAAT CPT code currently exists and where 87798 is the correct choice:

• Novel or emerging pathogens where no organism-specific CPT has been established
• Certain bacterial or fungal organisms tested by NAAT without a dedicated 87XXX code
• Select parasitic agents not covered by specific molecular codes

What 87798 does not cover

• Culture isolate testing: the AMA CPT Knowledge Base states 87798 applies to direct specimens. Applying it to culture isolates may be incorrect per AMA guidance.
• Any organism with a dedicated 87XXX code (see sibling codes below)
• Non-amplified probe techniques. Code 87797 covers non-amplified (direct probe) NOS detection
• Resistance targets that already have their own code. 87500 covers vancomycin resistance in enterococcus, and 87641 covers methicillin-resistant Staphylococcus aureus
• Panel codes where a multi-organism panel code already bundles the analytes

The chart below works through that order in one pass: dedicated code first, then method and organism count.

How the nucleic acid amplification procedure is documented

Understanding medical billing workflows for molecular diagnostics starts with the documentation chain between the ordering provider and the laboratory. For CPT 87798, every claim needs three elements to stand up under audit.

1. Physician order with organism specificity: the order must name the target organism or resistance gene, not just request “PCR panel.” Generic orders that don’t specify the analyte cannot support 87798 claims.
2. Medical necessity documentation: the clinical record must support why this specific pathogen was tested – signs, symptoms, exposure history, or prior treatment failure. Auditors look for that reasoning in the ordering provider’s record, not in the lab report.
3. Lab report confirming the method: the report must state “nucleic acid amplification” or equivalent (PCR, NAAT, RT-PCR) and identify the organism tested. A generic “molecular test” descriptor is insufficient.

Specimen type matters. Direct clinical specimens (swabs, urine, CSF, tissue) are the appropriate source for 87798. Labs that apply this code to culture isolates rather than direct specimens face recoupment risk under AMA guidance.

Codes commonly confused with 87798

The most frequent CPT 87798 errors involve reporting the NOS code when a specific organism code exists. Where a specific code covers both the organism and the method, that code is the one to report. Candida testing, for example, belongs under 87481. 87798 stays billable only for organisms that have no code of their own.

Note on CPT 87801. The code covers infectious agent detection by nucleic acid for multiple organisms, amplified probe technique. Before reporting several units of 87798 for one encounter, confirm with your MAC or the AMA whether 87801 is the correct choice instead. The two are not interchangeable, and the answer turns on what the assay itself reports.

Correct modifier usage for 87798

Modifier use for 87798 follows two core scenarios: multiple analytes in the same encounter, and situations where unbundling concerns arise.

Multiple NOS organisms in a single encounter

CPT 87798 is reported once per organism tested. If a lab tests for three NOS organisms from the same specimen in one encounter, three units of 87798 are billed. Most payers accept this per-analyte billing without a modifier. However, some MACs and commercial payers apply medically unlikely edits (MUEs) that cap units – check your MAC’s MUE table before billing high unit counts.

Modifier 59 application

Modifier 59 (distinct procedural service) applies when 87798 is reported alongside other lab codes and a payer’s bundling edits would otherwise deny the claim. Common scenario: reporting 87798 alongside a specific organism code (e.g., 87491) for a different organism tested in the same encounter. Modifier 59 signals that the services are clinically distinct.

• When to append Modifier 59: 87798 is denied as a bundled service alongside a specific NAAT code for a different organism
• When Modifier 59 is not needed: multiple units of 87798 alone for different NOS organisms
• What triggers an audit flag: Modifier 59 used repeatedly on the same code pair without clear documentation of distinct organisms

Medicare reimbursement rate and 87798 coverage

CPT 87798 is reimbursed under the CMS Clinical Laboratory Fee Schedule rather than the Physician Fee Schedule. The national limit amount for 87798 is about $35 per unit under the 2025 CLFS, and it carried through unchanged into 2026. Rates are updated each January, so check the current year’s figure in the CMS fee schedule before you quote it.

Coverage conditions for Medicare

• The lab must hold a CLIA certificate covering the complexity of the test performed
• A signed physician order must exist and be retained in the medical record
• Medical necessity must be documented in the ordering provider’s record, not just the lab report
• If coverage is uncertain, an Advance Beneficiary Notice (ABN) must be issued before testing begins

MolDX jurisdiction requirements for 87798

Labs billing a MolDX-participating Medicare Administrative Contractor (MAC) face requirements beyond the standard Medicare coverage rules. MolDX is a four-MAC program run by Palmetto GBA, Noridian, WPS and CGS, which between them cover 28 states. Novitas and NGS are the two non-MolDX MACs, and they apply standard LCD rules without the DEX Z-Code layer.

Achieving clean claim submission in a MolDX jurisdiction requires completing these steps before billing:

1. DEX Z-Code registration: the test must be registered with the MolDX DEX Z-Code system. Unregistered tests billed as 87798 in a MolDX jurisdiction are routinely denied, regardless of clinical appropriateness.
2. Technical assessment submission: the MolDX MACs require a technical assessment demonstrating analytical validity before the test can be approved for coverage. Approval comes first, and it is not granted retroactively.
3. LCD compliance: the test must fall within the coverage conditions of the applicable Local Coverage Determination. MolDX LCDs for molecular diagnostics specify acceptable clinical indications; testing outside those indications requires an ABN.
4. Documentation threshold: MolDX audits apply a higher documentation standard than the Novitas and NGS jurisdictions. Lab directors and billing teams should retain the full analytical validation package alongside patient-level records.

Scope note: MolDX requirements apply in the Palmetto GBA, Noridian, WPS and CGS jurisdictions, covering 28 states between them. If your lab bills Novitas or NGS, standard Medicare LCD rules apply and DEX Z-Code registration is not required for 87798.

Common denial reasons and how to prevent them

CPT 87798 denials cluster around a small set of patterns. Robust denial management workflows catch these before submission rather than after payment is refused.

Matching each rejection to the right denial code helps billing teams categorize molecular diagnostics rejections accurately and route appeals to the right queue.

OIG audit risk and compliance considerations

The Office of Inspector General (OIG) has documented scrutiny of high-volume PCR and NAAT panel billing. UTI panels draw particular attention, because 87798 has been reported there for multiple organisms across large patient populations.

Calling that pattern fraud without a confirmed legal finding would be inaccurate. The OIG identifies it as an audit-risk area and a compliance exposure, which is a different standard. Labs carrying high volumes of 87798 should treat that volume as a self-audit trigger.

Building defensible medical billing compliance programs for molecular diagnostics means addressing four areas proactively:

• Medical necessity policies: document in writing which clinical indications support ordering each NOS organism target. Generic “UTI panel” orders with no organism-specific rationale are the first records an auditor pulls.
• Reflex testing protocols: establish documented reflex criteria. Testing for additional organisms because a primary result was positive is defensible; reflexively adding organisms to every order is not.
• Self-audit cadence: run quarterly reports on 87798 unit volume by ordering provider. Outlier providers warrant a documentation review before a payer requests one.
• CLIA compliance: labs billing 87798 must hold a CLIA certificate that covers the complexity of the test performed. Complexity is assigned per test rather than by CPT code, so check the certificate against the assay.

How claims management software reduces 87798 denials

In most labs, an 87798 coding error surfaces only when the remittance arrives. By then the claim has been denied and the appeal clock has started. The same error is usually sitting on other claims in the same batch.

Pabau, the practice management platform we build, keeps the order, the clinical documentation and the claim in one patient record. Its claims software for labs submits electronically and processes ERA/835 remittances, so each denial comes back attached to the code that caused it.

That turns the quarterly self-audit into a report you can run. Unit volume by ordering provider, denial reasons by code, and appeal status all sit in the same place. An outlier shows up long before a payer asks about it.

Reduce lab billing denials with Pabau

Pabau’s claims management tools help clinical labs submit clean claims for molecular codes like CPT 87798. Denials are tracked by code, and submission connects straight to the clearinghouse.

Book a demo

Conclusion

CPT 87798 is a legitimate, billable code wherever it is used correctly. That means nucleic acid amplification on a direct specimen, for an organism with no dedicated CPT, billed one unit per analyte with medical necessity documented.

Two common causes of denials stand out. The first is a more specific code that existed and was not used. The second is a documentation chain between the ordering provider and the lab that did not support the claim. Close those two and the rest of the denial list gets considerably shorter.

Labs tightening the submission-to-payment cycle on molecular codes get there with revenue cycle management tools. Connecting straight to clearinghouse submission removes the manual rekeying where errors enter. Book a demo to see how Pabau handles claim submission, denial tracking and ERA processing for clinical labs.

Continue your research

Need to understand how denials flow through a clearinghouse? Electronic remittance advice (ERA) explains how 835 remittance files surface denial reason codes and payment adjustments for lab claims.

Want a structured overview of medical billing for lab providers? Superbill in medical billing covers how lab charges flow from the encounter to the payer.

Evaluating clearinghouse options for molecular lab claims? Medical claims clearinghouse guide compares clearinghouse types, payer connectivity, and submission workflows for clinical laboratories.

Frequently asked questions about 87798